Dark
Light
Today: September 25, 2024
March 1, 2024
1 min read

Boston’s February VC Funding Roundup: Which Startups Scored Big?

TLDR:

In this article, researchers have discovered a potential new treatment for Alzheimer’s disease involving a drug called Nilotinib. The drug has shown promise in mice studies by reducing the build-up of toxic proteins in the brain. Human trials are set to begin soon to further investigate the effectiveness of Nilotinib in treating Alzheimer’s.

A team of researchers have found that the drug Nilotinib has the potential to be a breakthrough treatment for Alzheimer’s disease. In studies conducted on mice, Nilotinib was found to reduce the accumulation of toxic proteins in the brain that are associated with Alzheimer’s.

The researchers are hopeful that Nilotinib could have similar effects in humans and are planning to conduct clinical trials to test its effectiveness in treating Alzheimer’s disease. If successful, Nilotinib could be a game-changer in the field of Alzheimer’s research and provide hope for millions of people affected by the disease.

Previous Story

Launch of Entourage: €277M Fund for European SaaS Founders

Next Story

Top Houston news: 2 VCs debut, RBPC participants revealed

Latest from Blog

Growing Cerity Partners: Merging with $15B VC Firm

TLDR: Cerity Partners merges with Touchdown Ventures, expanding venture capital capabilities Merge will enhance offerings to corporations and businesses, as well as private clients Cerity Partners, an independent wealth management firm, has
Go toTop